Leyden Laboratories
Develops antibody-based nasal sprays intended to prevent influenza and other respiratory-virus infections.
€40MSeries B
Role not disclosedGF
Gates Foundation
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Enterprise software · Jan 1, 2026
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $98.3M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionKanvas Biosciences
Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy
$48MSeries A
Role not disclosedHeritable Agriculture
Develops AI-driven crop improvement solutions for climate-resilient crops
$5MGrant
Role not disclosed